Novel drug delivery systems for glaucoma

Eye

Volumn 25, Issue 5, 2011, Pages 578-586

  Lavik, E ^a   Kuehn, M H ^b   Kwon, Y H ^b  

^a Case Western Reserve University   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

clinical trials; drug delivery; glaucoma; nanoparticle; PLGA

Indexed keywords

ANTIGLAUCOMA AGENT; BIMATOPROST; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBONATE DEHYDRATASE INHIBITOR; CILIARY NEUROTROPHIC FACTOR; DRUG CARRIER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LATANOPROST; LIPOSOME; NANOSPHERE; NEUROPROTECTIVE AGENT; OCULAR INSERT; PILOCARPINE; POLYMER; TIMOLOL; TIMOLOL MALEATE; TRAVOPROST; UNCLASSIFIED DRUG;

APPLICATION SITE DISCOLORATION; AQUEOUS HUMOR; BIOMEDICAL MICROELECTROMECHANICAL SYSTEM; BLOOD RETINA BARRIER; BLURRED VISION; CELL TRANSPLANTATION; CONJUNCTIVAL HYPEREMIA; COUGHING; DIARRHEA; DISEASE COURSE; DIURESIS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG IMPLANT; DRUG INDUCED HEADACHE; ELECTROLYTE DISTURBANCE; FATIGUE; GLAUCOMA; HUMAN; HYDROPHOBICITY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NAUSEA; NEUROPROTECTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; RETINA DETACHMENT; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; SOFT CONTACT LENS; VOMITING; WEIGHT REDUCTION;

EID: 79955996386     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.82     Document Type: Review

References (84)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80(5): 389-393. (Pubitemid 26158268)
2. Blomdahl S, Calissendorff BM, Tengroth B, Wallin O. Blindness in glaucoma patients. Acta Ophthalmol Scand 1997; 75(5): 589-591. (Pubitemid 28022354)
3. Munier A, Gunning T, Kenny D, O'Keefe M. Causes of blindness in the adult population of the Republic of Ireland. Br J Ophthalmol 1998; 82(6): 630-633. (Pubitemid 28306651)
4. Leske MC, Nemesure B, He Q, Wu SY, Hejtmancik JF, Hennis A. Patterns of open-angle glaucoma in the Barbados Family Study. Ophthalmology 2001; 108(6): 1015-1022. (Pubitemid 32500014)
5. Mukesh BN, McCarty CA, Rait JL, Taylor HR. Five-year incidence of open-angle glaucoma: the visual impairment project. Ophthalmology 2002; 109(6): 1047-1051. (Pubitemid 34546909)
6. Schoff EO, Hattenhauer MG, Ing HH, Hodge DO, Kennedy RH, Herman DC et al. Estimated incidence of open-angle glaucoma in Olmsted County, Minnesota. Ophthalmology 2001; 108(5): 882-886. (Pubitemid 32374243)
7. Friedman DS,Wolfs RC, O'Colmain BJ, Klein BE, Taylor HR, West S et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004; 122(4): 532-538. (Pubitemid 38456289)
8. Gurwitz JH, Glynn RJ, Monane M, Everitt DE, Gilden D, Smith N et al. Treatment for glaucoma: adherence by the elderly. Am J Pub Health 1993; 83(5): 711-716. (Pubitemid 23143002)
9. Schmier JK, Covert DW, Lau EC, Robin AL. Trends in annual medicare expenditures for glaucoma surgical procedures from 1997 to 2006. Arch Ophthalmol 2009; 127(7): 900-905.
10. Danesh-Meyer HV. Neuroprotection in glaucoma: recent and future directions. Curr Opin Ophthalmol 2011; 22(2): 78-86.
11. Baltmr A, Duggan J, Nizari S, Salt TE, Cordeiro MF. Neuroprotection in glaucoma: is there a future role? Exp Eye Res 2010; 91(5): 554-566.
12. AGIS Investigators T. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.. Am J Ophthalmol 2000; 130(4): 429-440.
13. Lotz B, Brooks B, Sanjak M, Weasler C, Roelke K, Parnell J et al. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996; 46(5): 1244-1249. (Pubitemid 26159280)
14. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998; 126(4): 498-505.
15. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121(1): 48-56. (Pubitemid 36401765)
16. Leskea MC, Heijl A, Hyman L, Bengtsson B, Komaroff E. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol 2004; 15(2): 102-106. (Pubitemid 38457128)
17. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007; 114(11): 1965-1972. (Pubitemid 350016362)
18. Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology 2006; 113(3): 431-436.
19. Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol 2008; 53(Suppl 1): S57-S68.
20. Rotchford AP, Murphy KM. Compliance with timolol treatment in glaucoma. Eye 1998; 12: 234-236. (Pubitemid 28263862)
21. Patrick M, Mitra AK. Overview of ocular drug delivery and iatrogenic ocluar cytopathologies. In: Mitra AK (ed). Ophthalmic Drug Delivery Systems. Marcel Dekker: New York, 1993, pp 1-27.
22. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging 2005; 22(1): 1-21. (Pubitemid 40188902)
23. Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther 2000; 22(2): 167-208.
24. Hoyng PF, van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs 2000; 59(3): 411-434.
25. Wilson RP, Kanal N, Spaeth GL. TimololFits effectiveness in different types of glaucoma. Ophthalmology 1979; 86(1): 43-50. (Pubitemid 9171535)
26. Zimmerman TJ, Kaufman HE. Beta-adrenergic blockingagent for treatment of glaucoma. Arch Ophthalmol 1977; 95(4): 601-604.
27. Linden C. Therapeutic potential of prostaglandin analogues in glaucoma. Expert Opin Investig Drugs 2001; 10(4): 679-694. (Pubitemid 32288186)
28. Schwartz SG, Flynn Jr HW. Fluocinolone acetonide implantable device for diabetic retinopathy. Curr Pharm Biotechnol 2011; 12(3): 347-351.
29. Loane DJ, Faden AI. Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol Sci 2010; 31(12): 596-604.
30. Danesh-Meyer HV, Levin LA. Neuroprotection: extrapolating from neurologic diseases to the eye. Am J Ophthalmol 2009; 148(2): 186-191e2.
31. Koeberle P, Ball A. Effects of GDNF on retinal ganglion cell survival following axotomy. Vision Res 1998; 38: 1505-1515. (Pubitemid 28239269)
32. Sendtner M, Schmalbruch H, Stockli KA, Carroll P, Kreutzberg GW, Thoenen H. Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature 1992; 358(6386): 502-504.
33. Maurer MH, Schabitz WR, Schneider A. Old friends in new constellationsFthe hematopoetic growth factors G-CSF, GM-CSF, and EPO for the treatment of neurological diseases. Curr Med Chem 2008; 15(14): 1407-1411. (Pubitemid 351997791)
34. Langer R. New methods of drug delivery. Science 1990; 249(4976): 1527-1533.
35. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006; 58(11): 1131-1135.
36. Di Polo A, Aigner LJ, Dunn RJ, Bray GM, Aguayo AJ. Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Muller cells temporarily rescues injured retinal ganglion cells. Proc Natl Acad Sci USA 1998; 95(7): 3978-3983.
37. Farjo R, Skaggs J, Quiambao AB, Cooper MJ, Naash MI. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS One 2006; 1: e38.
38. Thumann G, Stocker M, Maltusch C, Salz AK, Barth S, Walter P et al. High efficiency non-viral transfection of retinal and iris pigment epithelial cells with pigment epithelium-derived factor. Gene Therapy 2010; 17(2): 181-189.
39. Harper MM, Adamson L, Blits B, Bunge MB, Grozdanic SD, Sakaguchi DS. Brain-derived neurotrophic factor released from engineered mesenchymal stem cells attenuates glutamate- and hydrogen peroxide-mediated death of staurosporine-differentiated RGC-5 cells. Exp Eye Res 2009; 89(4): 538-548.
40. Realini T. A history of glaucoma pharmacology. Optom Vis Sci 2011; 88(1): 36-38.
41. Toris CB. Pharmacotherapies for glaucoma. Curr Mol Med 2010; 10(9): 824-840.
42. Genead MA, Fishman GA. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome. Arch Ophthalmol 2010; 128(9): 1146-1150.
43. Sivaprasad S, Bunce C, Wormald R. Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br J Ophthalmol 2005; 89(11): 1420-1422. (Pubitemid 41527373)
44. Ghate D, Edelhauser HF. Barriers to glaucoma drug delivery. J Glaucoma 2008; 17(2): 147-156. (Pubitemid 351412405)
45. Worakul N, Robinson JR. Ocular pharmacokinetics/ pharmacodynamics. Eur J Pharm Biopharm 1997; 44(1): 71-83.
46. Shedden A, Laurence J, Tipping R. Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution vs timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, doublemasked, multicenter study. Clin Ther 2001; 23(3): 440-450. (Pubitemid 32328749)
47. Uusitalo H, Nino J, Tahvanainen K, Turjanmaa V, Ropo A, Tuominen J et al. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Acta Ophthalmol Scand 2005; 83(6): 723-728. (Pubitemid 41819296)
48. Uusitalo H, Kahonen M, Ropo A, Maenpaa J, Bjarnhall G, Hedenstrom H et al. Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma. Graefes Arch Clin Exp Ophthalmol 2006; 244(11): 1491-1496. (Pubitemid 44741262)
49. Macoul KL, Pavan-Langston D. Pilocarpine ocusert system for sustained control of ocular hypertension. Arch Ophthalmol 1975; 93(8): 587-590.
50. Pollack IP, Quigley HA, Harbin TS. Ocusert pilocarpine system-advantages and disadvantages. South Med J 1976; 69(10): 1296-1298.
51. Saettone MF, Salminen L. Ocular inserts for topical delivery. Adv Drug Deliv Rev 1995; 16(1): 95-106.
52. Urtti A, Rouhiainen H, Kaila T, Saano V. Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans. Pharm Res 1994; 11(9): 1278-1282. (Pubitemid 24287406)
53. Stewart RH, Novak S. Introduction of the ocusert ocular system to an ophthalmic practice. Ann Ophthalmol 1978; 10(3): 325-330. (Pubitemid 8329382)
54. Haller JA, Bandello F, Belfort Jr R, Blumenkranz MS, Gillies M, Heier J et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117(6): 1134-1146.e3.
55. Thanos CG, Bell WJ, O'Rourke P, Kauper K, Sherman S, Stabila P et al. Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT- 501 intraocular device. Tissue Eng 2004; 10(11-12): 1617-1622. (Pubitemid 40054203)
56. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 2006; 103(10): 3896-3901. (Pubitemid 43376652)
57. Monem AS, Ali FM, Ismail MW. Prolonged effect of liposomes encapsulating pilocarpine HCl in normal and glaucomatous rabbits. Int J Pharm 2000; 198(1): 29-38.
58. De Campos AM, Sanchez A, Gref R, Calvo P, Alonso MJ. The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci 2003; 20(1): 73-81. (Pubitemid 37103234)
59. Uchida T. Introduction of macromolecules into mammalian cells by cell fusion. Exp Cell Res 1988; 178(1): 1-17.
60. American Academy of Ophthalmology. Eye Health Statistics at a Glance, 2009. Available at newsroom/press-kit/upload/Eye-Health-Statistics-June- 2009.pdf.
61. White CJ, Byrne ME. Molecularly imprinted therapeutic contact lenses. Expert Opin Drug Deliv 2010; 7(6): 765-780.
62. Hoffman A. Hydrogels for biomedical applications. Adv Drug Deliv Rev 2002; 54(1): 3-12. (Pubitemid 34081178)
63. Peppas N, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm 2000; 50(1): 27-46.
64. Hiratani H, Alvarez-Lorenzo C. Timolol uptake and release by imprinted soft contact lenses made of N,Ndiethylacrylamide and methacrylic acid. J Control Release 2002; 83(2): 223-230. (Pubitemid 35279467)
65. Schultz CL, Poling TR, Mint JO. A medical device/drug delivery system for treatment of glaucoma. Clin Exp Optom 2009; 92(4): 343-348.
66. Saati S, Lo R, Li PY, Meng E, Varma R, Humayun MS. Mini drug pump for ophthalmic use. Trans Am Ophthalmol Soc 2009; 107: 60-70.
67. Saati S, Lo R, Li PY, Meng E, Varma R, Humayun MS. Mini drug pump for ophthalmic use. Curr Eye Res 2010; 35(3): 192-201.
68. Staples M, Daniel K, Cima MJ, Langer R. Application of micro- and nano-electromechanical devices to drug delivery. Pharm Res 2006; 23(5): 847-863. (Pubitemid 43781393)
69. Kim TW, Lindsey JD, Aihara M, Anthony TL, Weinreb RN. Intraocular distribution of 70-kDa dextran after subconjunctival injection in mice. Invest Ophthalmol Vis Sci 2002; 43(6): 1809-1816. (Pubitemid 34587025)
70. Mansoor S, Kuppermann BD, Kenney MC. Intraocular sustained-release delivery systems for triamcinolone acetonide. Pharm Res 2009; 26(4): 770-784.
71. Okabe K, Kimura H, Okabe J, Kato A, Kunou N, Ogura Y. Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest Ophthalmol Vis Sci 2003; 44(6): 2702-2707. (Pubitemid 36618433)
72. Bao W, Zhou J, Luo J, Wu D. PLGA microspheres with high drug loading and high encapsulation efficiency prepared by a novel solvent evaporation technique. J Microencapsul 2006; 23(5): 471-479. (Pubitemid 44446590)
73. Fu K, Harrell R, Zinski K, Um C, Jaklenec A, Frazier J et al. A potential approach for decreasing the burst effect of protein from PLGA microspheres. J Pharm Sci 2003; 92(8): 1582-1591. (Pubitemid 36929678)
74. Shive M, Anderson J. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28(1): 5-24. (Pubitemid 27497671)
75. Cardillo JA, Paganelli F, Melo Jr LA, Silva Jr AA, Pizzolitto AC, Oliveira AG. Subconjunctival delivery of antibiotics in a controlled-release system: a novel anti-infective prophylaxis approach for cataract surgery. Arch Ophthalmol 2010; 128(1): 81-87.
76. Kang SJ, Durairaj C, Kompella UB, O'Brien JM, Grossniklaus HE. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch Ophthalmol 2009; 127(8): 1043-1047.
77. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol 2005; 511(2-3): 191-198. (Pubitemid 40417726)
78. Namur JA, Cabral-Albuquerque EC, Quintilio W, Santana MH, Politi MJ, de Araujo PS et al. Poly-lactide-coglycolide microparticle sizes: a rational factorial design and surface response analysis. J Nanosci Nanotechnol 2006; 6(8): 2403-2407. (Pubitemid 44599065)
79. Bertram J, Saluja SS, McKain JA, Lavik EB. Sustained delivery of timolol maleate from poly(lactic-co-glycolicacid)/poly(lactic acid) microspheres for over 3 months. J Microencapsul 2009; 26(1): 18-26.
80. Lee TWY, Robinson JR. Drug delivery to the posterior segment of the eye II: development and validation of a simple pharmacokinetic model for subconjunctival injection. J Ocul Pharmacol Ther 2004; 20(1): 43-53. (Pubitemid 38199331)
81. Seiler MJ, Thomas BB, Chen Z, Arai S, Chadalavada S, Mahoney MJ et al. BDNF-treated retinal progenitor sheets transplanted to degenerate rats: improved restoration of visual function. Exp Eye Res 2008; 86(1): 92-104. (Pubitemid 350218138)
82. Grozdanic SD, Lazic T, Kuehn MH, Harper MM, Kardon RH, Kwon YH et al. Exogenous modulation of intrinsic optic nerve neuroprotective activity. Graefes Arch Clin Exp Ophthalmol 2010; 248(8): 1105-1116.
83. Ward MS, Khoobehi A, Lavik EB, Langer R, Young MJ. Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres. J Pharm Sci 2007; 96(3): 558-568. (Pubitemid 46466078)
84. Kyhn M, Klassen H, Johansson U, Warfvinge K, Lavik E, Kiilgaard J et al. Delayed administration of glial cell line-derived neurotrophic factor (GDNF) protects retinal ganglion cells in a pig model of acute retinal ischemia. Exp Eye Res 2009; 89(6): 1012-1020.